MarketPulse
I

$IOVA

8 articles found
3 positive
0 negative
5 neutral
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Iovance Stock Could Soar 165% on Cancer Drug Success, Despite Manufacturing Risks

Iovance Biotherapeutics surged 34% in 2026 on strong melanoma drug sales, with analysts projecting 165% upside. Manufacturing challenges present significant execution risks.
IOVAregulatory riskstock valuation
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Iovance's Cell Therapy Bet: $1B Revenue Dream Amid Manufacturing Headwinds

Iovance's Amtagvi cancer therapy targets $1B+ revenue by 2030 amid strong early growth, but faces manufacturing cost and regulatory risks.
IOVAbiotechoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Proleukin Market Set to Expand 6.1% Annually Through 2030 Amid Cancer, CF Growth

Proleukin market projected to grow 6.1% annually to $1.68M by 2030, driven by rising cancer prevalence and expanded indications. Iovance Biotherapeutics strengthens position via 2023 acquisition.
NVSIOVAcancer treatmentcystic fibrosis
BenzingaBenzinga··Usa News Group

$578B Regenerative Medicine Market Faces Manufacturing Crisis as Avaí Bio Pioneers Cell Banking Solution

Regenerative medicine market projected at $578B faces manufacturing bottleneck as Avaí Bio advances Master Cell Bank solution enabling scalable, off-the-shelf cell therapy production.
PRMEIOVAAVAIMDGLDNLIFDA approvalregenerative medicine
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Iovance's Personalized Cancer Therapy Targets 60%+ Growth, But Execution Risk Looms

Iovance shows 60.6% fiscal 2025 revenue growth for its personalized cancer therapy Amtagvi, but faces manufacturing complexity and profitability challenges ahead.
IOVAFDA approvalbiotech
The Motley FoolThe Motley Fool··Adria Cimino

Iovance Biotherapeutics Expands Market Presence Following Amtagvi Approval

Iovance's newly approved melanoma therapy Amtagvi generated $68M in quarterly revenue with strong 52% response rates, positioning the biotech for pipeline expansion across multiple cancer indications.
IOVAbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Iovance Grants Stock Options to New Employees Under NASDAQ Inducement Plan

Iovance granted 3,600 stock options to two new employees at $2.85/share under NASDAQ inducement plan rules, with three-year vesting.
IOVAvesting schedulebiotechnology
The Motley FoolThe Motley Fool··Josh Kohn-Lindquist

ImmunityBio Gains 41% Following European Approval of Bladder Cancer Therapy

ImmunityBio shares surged 41% after Europe approved its bladder cancer therapy ANKTIVA, enabling commercialization across 30+ nations and opening significant revenue opportunities.
IBRXIOVAKRYSbiotechbladder cancer